CollPlant Biotechnologies (NASDAQ:CLGN) Issues Quarterly Earnings Results

CollPlant Biotechnologies (NASDAQ:CLGN) released its quarterly earnings results on Thursday. The company reported ($0.90) EPS for the quarter, missing the consensus estimate of ($0.19) by ($0.71), FiscalAI reports. CollPlant Biotechnologies had a negative net margin of 491.31% and a negative return on equity of 102.00%. The business had revenue of $0.06 million during the quarter, compared to analyst estimates of $6.78 million.

CollPlant Biotechnologies Trading Down 11.4%

NASDAQ:CLGN opened at $0.67 on Thursday. The firm has a market capitalization of $8.51 million, a price-to-earnings ratio of -0.65 and a beta of 3.02. CollPlant Biotechnologies has a 1-year low of $0.50 and a 1-year high of $4.98. The business’s fifty day moving average price is $0.96 and its 200 day moving average price is $1.70.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently issued reports on CLGN shares. Weiss Ratings restated a “sell (e+)” rating on shares of CollPlant Biotechnologies in a report on Wednesday, January 21st. D. Boral Capital lowered CollPlant Biotechnologies from a “buy” rating to a “hold” rating in a research note on Friday, February 6th. One investment analyst has rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $11.50.

CollPlant Biotechnologies Company Profile

CollPlant Biotechnologies Ltd. (NASDAQ: CLGN) is a regenerative medicine company that develops and commercializes recombinant human collagen (rhCollagen) and 3D bioprinting technologies for medical and aesthetic applications. The company’s proprietary plant-based rhCollagen is produced using genetically engineered tobacco plants to provide a scalable, animal-free source of human collagen that meets regulatory standards.

CollPlant’s product portfolio includes Vergenix™ wound care matrices and dermal fillers for aesthetic and reconstructive purposes, as well as a range of bioinks designed for 3D bioprinting of soft and hard tissues.